Balyasny Asset Management
SION

Balyasny Asset Management’s Sionna Therapeutics SION Stock Holding History

Balyasny Asset Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,406
Closed -$57.8K – 3684
2025
Q4 		$57.8K Buy
+1,406
New +$53.3K ﹤0.01% 3002
2025
Q2 		– Sell
-13,060
Closed -$137K – 3485
2025
Q1 		$137K Buy
+13,060
New +$213K ﹤0.01% 2655

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's SION Position: Q1 2026 in Review

Balyasny Asset Management sold out of Sionna Therapeutics (SION) in Q1 2026, closing a stake of 1,406 shares — an estimated $57.8K sold.

Balyasny Asset Management first reported a position in SION in Q1 2025 and held it in 2 quarters. The position peaked at $137K in Q1 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Balyasny Asset Management reported no remaining Sionna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 1,406 Sionna Therapeutics shares in Q1 2026, an estimated $57.8K.
  • Balyasny Asset Management first reported a position in Sionna Therapeutics in Q1 2025 and held it in 2 quarters.
  • Balyasny Asset Management's Sionna Therapeutics position peaked at $137K in Q1 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.